• Aliases: SU6668, TSU-68
    • Antiangiogenesis inhibitor of VEGFR-2, FGFR, and PDGFR also inhibits KIT and MAPK
    • Currently under investigation in phase 3 clinical trial with HCC
    • Recommended phase 3 dose: 200 mg/m2 orally b.i.d. or 100 mg/m2 t.i.d. with food
    • Half-life: 2 to 4 hours (terminal)
    • Metabolism: Possible CYP3A4 substrate
    • Common side effects: Anorexia, nausea/vomiting, diarrhea, fatigue, flu-like symptoms, myalgia/arthralgia, abdominal pain, chest pain, anemia
    (Keunen et al., 2005)
    Other topics in Targeted and Immunotherapy Agents